Table 5.
Comparison between observed and predicted pharmacokinetic parameters with their observed/predicted ratios, average fold error and root mean square error in healthy, tuberculosis and cirrhosis populations following i.v and oral rifampicin administration.
| Parameters | Mean Ratioobs/pred (Range) | AFE | RMSE |
|---|---|---|---|
| Intravenous Application in Healthy Population | |||
| AUC0–∞ (µg/mL·h) | 0.82 (0.76–0.89) | 0.78 | 19.39 |
| CL (L/h) | 1.28 (1.26–1.31) | 1.27 | 1.78 |
| Cmax (µg/mL) | 1.16 (1.04–1.27) | 1.14 | 1.96 |
| Oral Application in Healthy Population | |||
| AUC0–∞ (µg/mL·h) | 0.84 (0.51–1.47) | 0.80 | 51.80 |
| CL (L/h) | 1.22 (0.65–1.86) | 1.14 | 2.83 |
| Cmax (µg/mL) | 0.88 (0.36–1.67) | 0.79 | 5.95 |
| Oral Application in Tuberculosis Population | |||
| AUC0–∞ (µg/mL·h) | 0.96 (0.69–1.31) | 0.93 | 16.10 |
| CL (L/h) | 1.08 (0.76–1.42) | 1.02 | 1.04 |
| Cmax (µg/mL) | 0.69 (0.46–0.85) | 0.66 | 13.82 |
| Oral Application in Liver Cirrhosis Population | |||
| AUC0–∞ (µg/mL·h) | 1.09 (0.87–1.38) | 1.30 | 11.27 |
| CL (L/h) | 0.94 (0.72–1.14) | 0.98 | 0.009 |
| Cmax (µg/mL) | 1.19 (0.99–1.46) | 1.10 | 2.67 |
Ratio(obs/pred): observed/predicted ratio for the pharmacokinetic parameter, AFE: average fold error, RMSE: root mean square error.